Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Immunosuppressive Medicines Do Not Worsen COVID-19 Outcomes

Reuters Staff  |  February 17, 2021

(Reuters)—Medications that suppress the immune system—necessary for many chronic diseases—do not worsen outcomes of COVID-19 cases, new data suggest. Researchers looked back at 2,121 adults hospitalized for COVID-19 between March and August, including 108 who were taking immunosuppressive drugs (primarily prednisone, tacrolimus or mycophenolate mofetil). After accounting for patients’ general baseline health status, researchers found…

Filed under:Drug Updates Tagged with:COVID-19hospitalizedimmunosuppressive drugs

The Effects of IL-17A Inhibitors on the Microbiota

Vanessa Caceres  |  February 16, 2021

The use of an interleukin (IL) 17A inhibitor resulted in gut microbial dysbiosis and features of subclinical intestinal inflammation in a subgroup of psoriatic arthritis (PsA) and spondyloarthritis (SpA) patients, according to a multidisciplinary, collaborative study across several institutions published in Arthritis & Rheumatology.1 Understanding the downstream effects of these perturbations is an important step…

Filed under:Axial SpondyloarthritisConditionsPsoriatic ArthritisResearch Rheum Tagged with:gut microbiotaMicrobiomePsoriatic Arthritissecukinumab

Rheum After 5: Dr. Angus Worthing, the Singing Rheumatologist

Carol Patton  |  February 16, 2021

Every Christmas Eve, Angus Worthing, MD, FACP, FACR, his wife, Margaret, and two young children, engage in a sing-off over the phone, competing against a professional quartet comprising his best friend, Doug, Doug’s sister and their parents. Dr. Worthing, a partner at Arthritis & Rheumatism Associates in Washington, D.C., demonstrated his musical talent as a…

Filed under:AudioProfilesRheum After 5 Tagged with:Dr. Angus Worthing

The ACR’s 2020 Advocacy Year in Review

Blair Solow, MD, & Zachary Wallace, MD, MSc  |  February 16, 2021

To say it has been an interesting (the science and the memes), tumultuous (the politics) and heartbreaking (the pandemic and social injustice) year is an understatement. There have been moments of grace and inspiration that we hope have kept everyone going.  As we look to 2021, we take lessons from our experiences in 2020. Washington,…

Filed under:From the CollegeLegislation & Advocacy Tagged with:Centers for Medicare & Medicaid Services (CMS)RheumPACstep therapytelehealthU.S. Congress

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD  |  February 16, 2021

Drug-induced lupus erythe­matosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)…

Filed under:ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ANCA-Associated Vasculitiscase reporthydralazine

Study Finds Renal Arteriosclerosis Is Common in Lupus Nephritis Patients

Mary Beth Nierengarten  |  February 16, 2021

Renal arteriosclerosis is common in lupus patients with nephritis and occurs two decades earlier than it does in people without lupus nephritis (LN), report investigators in a study that examined the prevalence of renal arteriosclerosis in LN patients compared with healthy controls.1  The finding suggests that renal arteriosclerosis could be used as a biomarker for…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:Cardiovascular diseaseLupus nephritisrenal arterialsclerosis

Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

William J. Scheuing, MD, Nitasha Kumar, MD, William Davis, MD, & Robert Quinet, MD  |  February 16, 2021

Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

Filed under:ConditionsVasculitis Tagged with:ANCA-Associated Vasculitiscase reporthydralazinepulmonary-renal syndrome

Lost and found

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  February 16, 2021

Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

Filed under:ConditionsSystemic Sclerosis Tagged with:Lost & FoundRenal disease

The Character of Rheumatology Has Changed Over the Past 50 Years

Bruce Rothschild, MD  |  February 16, 2021

Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheuma­tology in the halcyon days of the 1970s and 80s.  That’s not to belittle the world we now live in, with so many treatment options for our…

Filed under:OpinionQuality Assurance/ImprovementSpeak Out Rheum Tagged with:imagingphysical examSpeak Out RheumatologyTesting

Point-of-Care Testing for COVID-19

Philip Seo, MD, MHS  |  February 16, 2021

Ethan Craig was not pleased. As a reader of this column, you know that Dr. Craig is an assistant professor of clinical medicine in the Division of Rheumatology at the University of Pennsylvania and an associate editor of The Rheumatologist. On this particular morning, however, he was the father of a 5-year-old who woke up…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19Testingvaccines

  • « Previous Page
  • 1
  • …
  • 76
  • 77
  • 78
  • 79
  • 80
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences